Volume 15, Issue 2 (Int J Mol Cell Med 2026)                   Int J Mol Cell Med 2026, 15(2): 1409-1419 | Back to browse issues page


XML Print


1- Department of Medical Laser, Medical Laser Research Center, Yara Institute, ACECR, Tehran, Iran.
2- Department of Photodynamic, Medical Laser Research Center, Yara Institute, ACECER, Tehran. Iran
3- Department of Medical Laser, Medical Laser Research Center, Yara Institute, ACECR, Tehran, Iran. , tabaie@acecr.ac.ir
Abstract:   (693 Views)

Mesenchymal stem cell-conditioned media (MSC-CM) represents a promising cell-free therapeutic strategy in regenerative medicine, leveraging the paracrine effects of stem cells. Standardized biochemical characterization of MSC-CM is crucial for ensuring its reproducibility and therapeutic potential. However, statistical validation of batch-to-batch reproducibility has been rarely reported. Therefore, this study aimed to establish a reproducible protocol for AD-MSC-CM production and quantitatively demonstrate batch-to-batch reproducibility of total protein and key growth factors. Adipose-derived MSCs (AD-MSCs) were isolated from rat adipose tissue, expanded, and used to produce conditioned media (MSC-CM). The MSC-CM was biochemically profiled using the Bradford assay for total protein concentration and specific enzyme-linked immunosorbent assays (ELISAs) for quantifying Transforming Growth Factor-Beta (TGF-β) and Vascular Endothelial Growth Factor (VEGF). Analyses were performed on three independent biological replicates. The MSC-CM showed a significant and consistent increase in total protein concentration compared to control serum-free medium. Quantitative analysis revealed reproducible and stable secretion of key growth factors. The concentrations of both TGF-β and VEGF showed no significant variation across the biological replicates, confirming the high reproducibility of the MSC-CM preparation protocol. This study established a robust method for generating reproducible AD-MSC-CM, characterized by a stable and enriched content of total protein and specific growth factors (TGF-β and VEGF). The findings confirm the reliability of the production process and highlight the hypothesized potential of this well-characterized MSC-CM as a consistent therapeutic agent for applications requiring immunomodulation and angiogenesis, pending direct functional validation.

Full-Text [PDF 909 kb]   (311 Downloads)    
Systematic Reviews and Meta-Analyses: Original Article | Subject: Stem Cell

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.